Relay Therapeutics, Inc.
RLAY
Peringkat dalam Saham
#4007
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Harga Saham
$18.65
Terakhir disinkronkan: 2026-10-20
Kapitalisasi Pasar
$4.09B
Perubahan (1 hari)
9.15%
Perubahan (1 tahun)
164.96%
Negara
US
Perdagangan Relay Therapeutics, Inc. (RLAY)
Kategori
Healthcare
Pendapatan untuk Relay Therapeutics, Inc. (RLAY)
Pendapatan pada Jun 2026 TTM: $10.35M
Menurut laporan keuangan terbaru dari Relay Therapeutics, Inc., pendapatan saat ini (TTM) adalah $10.35M. Pada tahun 2023, perusahaan menghasilkan pendapatan sebesar $25.55M peningkatan dibandingkan pendapatan pada tahun 2022 yang sebesar $1.38M. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Relay Therapeutics, Inc. dari 2018 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Mengubah |
|---|---|---|
| 2026 (TTM) | $10.35M | 3.43% |
| 2024 | $10.01M | -60.83% |
| 2023 | $25.55M | 1,749.82% |
| 2022 | $1.38M | -54.41% |
| 2021 | $3.03M | -96.34% |
| 2020 | $82.65M | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan | Pendapatan | Perbedaan Pendapatan | Negara |
|---|---|---|---|
| $12.62B | 121,873.91% |
US
|
|
| $2.23B | 21,426.57% |
US
|
|
| $15.74B | 152,019.10% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 58,076.69% |
NL
|
